| Literature DB >> 36262392 |
Makito Yamada1, Yu Hirose2, Bangzhong Lin1, Megumi Fumimoto1, Kazuto Nunomura1, Sirimangkalakitti Natchanun1, Naoyuki Takahashi3, Yuuta Ohki3, Makoto Sako1, Kenichi Murai1, Kazuo Harada1, Masayoshi Arai1, Sayo Suzuki2, Tomonori Nakamura2, Junichi Haruta1, Mitsuhiro Arisawa1.
Abstract
Monoamine oxidase B (MAO-B) metabolizes monoamines such as dopamine regarding neural transmission and controls its level in the mammalian's brain. When MAO-B metabolizes dopamine abnormally, normal neurotransmission does not occur, and central nervous system disorders such as Parkinson's disease may develop. Although several MAO inhibitors have been developed, most of them have no selectivity between monoamine oxidase A (MAO-A) and MAO-B, or they work irreversibly against the enzyme. This report describes the first case of screening of N-arylated heliamine derivatives to develop novel MAO-B selective inhibitors that can be synthesized concisely by microwave-assisted Pd nanoparticle-catalyzed Buchwald-Hartwig amination. We discovered that the derivatives 4h, 4i, and 4j display inhibitory activity against MAO-B with IC50 values of 1.55, 13.5, and 5.08 μM, respectively.Entities:
Year: 2022 PMID: 36262392 PMCID: PMC9575162 DOI: 10.1021/acsmedchemlett.2c00228
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632